SCHEMBL2439702

SCHEMBL2439702

Cn1c(=O)cc(O)c2cc(I)cnc21

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.38
ALDH1A1 P00352 3/20 0.38
HPGD P15428 3/20 0.38
KDM4E B2RXH2 3/20 0.38
MAPT P10636 2/20 0.38
THRB P10828 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.34
TET2 Q6N021 2/20 0.33
HTT P42858 1/20 0.33
MEN1 O00255 1/20 0.32
LMNA P02545 1/20 0.32
PABPC1 P11940 1/20 0.32
KMT2A Q03164 1/20 0.32
MAP2K1 Q02750 3/20 0.32
COMT P21964 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5871967 0.72 FEN1 (0.54) HSD17B10ALDH1A1HPGDKDM4EMAPT
SCHEMBL2437609 0.71 PDE3B (0.35) HSD17B10ALDH1A1HPGDKDM4EMAPT
SCHEMBL2436829 0.71 HSD17B10 (0.33) HSD17B10HPGDHTTMEN1LMNA
SCHEMBL20680340 0.70 KDM4E (0.50) HSD17B10ALDH1A1HPGDKDM4EMAPT
SCHEMBL2434416 0.69 ALDH1A1 (0.44) HSD17B10ALDH1A1HPGDKDM4EMAPT
SCHEMBL23117578 0.69 KDM4E (0.39) HSD17B10ALDH1A1HPGDKDM4EMAPT
SCHEMBL11591420 0.67 KDM4E (0.46) HSD17B10ALDH1A1HPGDKDM4EMAPT
SCHEMBL2582874 0.64 L3MBTL1 (0.42) ALDH1A1HPGDKDM4EMAPTNPSR1
SCHEMBL2434550 0.64 ADORA1 (0.45) HSD17B10ALDH1A1HPGDKDM4EMAPT
SCHEMBL11589606 0.64 ALDH1A1 (0.54) HSD17B10ALDH1A1HPGDKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142509-B1 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC (US) 2013-12-04 EP disclosed
US-8349868-B2 Azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2013-01-08 US disclosed
US-8048894-B2 Quinolones and azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2011-11-01 US disclosed
US-20110224248-A1 AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC. (US) 2011-09-15 US disclosed
EP-2142509-A2 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE Amgen, Inc (US) 2010-01-13 EP disclosed
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase AMGEN INC. (US) 2009-06-18 US disclosed
WO-2008130600-A2 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC. (US) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase EGLN3, HIF1AN, EGLN2 HSD17B10 692/4885ALDH1A1 191/4885HPGD 29/4885
US-20110224248-A1 AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE HIF1AN, EGLN3, EGLN2 HSD17B10 465/4885ALDH1A1 145/4885HPGD 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.